• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.妊娠期人类免疫缺陷病毒感染患者在妊娠晚期埃替拉韦（elvitegravir）暴露量显著降低：来自感染 HIV 的妊娠妇女中抗逆转录病毒药物药代动力学网络（PANNA）的研究数据。
Clin Infect Dis. 2020 Dec 17;71(10):e714-e717. doi: 10.1093/cid/ciaa488.
2
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.HIV 感染孕妇及产后女性中埃替拉韦/考比司他的药代动力学。
AIDS. 2018 Nov 13;32(17):2507-2516. doi: 10.1097/QAD.0000000000001992.
3
Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.整合酶抑制剂艾维雷格和多替拉韦在 HIV 感染孕妇中的药代动力学和安全性。
Ann Pharmacother. 2019 Aug;53(8):833-844. doi: 10.1177/1060028019830788. Epub 2019 Feb 10.
4
The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.妊娠对人类免疫缺陷病毒感染者体内多拉韦林及其主要代谢物的总浓度和游离浓度的药代动力学的影响。
Clin Infect Dis. 2021 Jan 23;72(1):121-127. doi: 10.1093/cid/ciaa006.
5
Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.马拉维若在感染HIV-1的孕妇中的药代动力学。
Clin Infect Dis. 2015 Nov 15;61(10):1582-9. doi: 10.1093/cid/civ587. Epub 2015 Jul 22.
6
Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.拉替拉韦在感染 HIV-1 的孕妇中的药代动力学、安全性和疗效。
Clin Infect Dis. 2015 Sep 1;61(5):809-16. doi: 10.1093/cid/civ366. Epub 2015 May 5.
7
Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.妊娠晚期人类免疫缺陷病毒 1 型感染妇女中利匹韦林暴露降低。
Clin Infect Dis. 2017 Oct 15;65(8):1335-1341. doi: 10.1093/cid/cix534.
8
Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.含考比司他的抗逆转录病毒治疗方案不建议在妊娠期使用：观点。
AIDS. 2019 May 1;33(6):1089-1093. doi: 10.1097/QAD.0000000000002163.
9
First reported use of elvitegravir and cobicistat during pregnancy.首次报道在孕期使用埃替格韦和考比司他。
AIDS. 2016 Mar 13;30(5):807-8. doi: 10.1097/QAD.0000000000000976.
10
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.在初治的 HIV 感染青少年中，含有艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺的单片复方制剂的安全性、疗效和药代动力学：一项单臂、开放标签试验。
Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.

引用本文的文献

1
Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib.考比司他的群体药代动力学及其对抗癌药物奥拉帕利药代动力学的影响。
Clin Pharmacokinet. 2025 Mar;64(3):425-435. doi: 10.1007/s40262-025-01480-w. Epub 2025 Feb 5.
2
Antiretroviral Options and Treatment Decisions During Pregnancy.孕期抗逆转录病毒治疗方案与治疗决策
Paediatr Drugs. 2023 May;25(3):267-282. doi: 10.1007/s40272-023-00559-w. Epub 2023 Feb 2.
3
HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.HIV-1整合酶链转移抑制剂与神经发育
Pharmaceuticals (Basel). 2022 Dec 9;15(12):1533. doi: 10.3390/ph15121533.
4
Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse Models.第二代人类免疫缺陷病毒整合酶抑制剂诱导人类胚胎干细胞和小鼠模型分化失调并产生毒性作用。
J Infect Dis. 2022 Nov 28;226(11):1992-2001. doi: 10.1093/infdis/jiac386.
5
Magnitude of Drug-Drug Interactions in Special Populations.特殊人群中药物相互作用的程度。
Pharmaceutics. 2022 Apr 4;14(4):789. doi: 10.3390/pharmaceutics14040789.
6
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.替诺福韦艾拉酚胺血浆浓度在感染人类免疫缺陷病毒（HIV）的孕妇中降低：来自 PANNA 网络的数据。
Clin Infect Dis. 2022 Sep 10;75(4):623-629. doi: 10.1093/cid/ciab1010.
7
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.地塞米松是一种剂量依赖性的药物相互作用的促成剂：对 HIV 感染者的应用的影响。
J Antimicrob Chemother. 2022 Feb 23;77(3):568-573. doi: 10.1093/jac/dkab412.
8
Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?抗逆转录病毒药物在 HIV 感染孕妇中的药物相互作用：与非孕妇有何不同？
Clin Pharmacokinet. 2020 Oct;59(10):1217-1236. doi: 10.1007/s40262-020-00914-x.

妊娠期人类免疫缺陷病毒感染患者在妊娠晚期埃替拉韦（elvitegravir）暴露量显著降低：来自感染 HIV 的妊娠妇女中抗逆转录病毒药物药代动力学网络（PANNA）的研究数据。

Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.

机构信息

Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Saint-Pierre University Hospital, Brussels, Belgium.

出版信息

Clin Infect Dis. 2020 Dec 17;71(10):e714-e717. doi: 10.1093/cid/ciaa488.

DOI:10.1093/cid/ciaa488
PMID:32330231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7744974/
Abstract

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.

摘要

这项 4 期研究调查了妊娠对 14 名人类免疫缺陷病毒 1 型妇女中埃替拉韦/考比司他药代动力学的影响。结果支持不建议在妊娠期间使用埃替拉韦/考比司他，因为在给药间隔结束时（Ctrough）的埃替拉韦浓度降低了 77%，85%的孕妇的 Ctrough 低于有效浓度（EC90）。临床试验注册。NCT00825929。